Skip to main content
Clinical Trials/NCT05158257
NCT05158257
Recruiting
Not Applicable

Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity

Xuanwu Hospital, Beijing1 site in 1 country144 target enrollmentSeptember 30, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atherosclerosis
Sponsor
Xuanwu Hospital, Beijing
Enrollment
144
Locations
1
Primary Endpoint
12-month Primary Patency Rate
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

This is a Prospective randomized controlled study to evaluate the difference of safety,effectiveness between endovascular debulking combined drug-coated balloon and balloon dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions.

Detailed Description

Prospective randomized controlled study to evaluate the difference of safety,effectiveness between endovascular debulking combined drug-coated balloon and balloon dilatation combined stent angioplasty in treatment of femoral-popliteal artery lesions. Patients with femoral-popliteal artery lesions in our department were randomly assigned to the endovascular debulking combined drug-coated balloon group and balloon dilatation combined with stent angioplasty group. Compare the ischemic improvement rate (limb salvage rate, postoperative patency rate) and the complications rate of two different treatments. At the same time, the peri-operative related factors that may affect the end point events, such as preoperative baseline data, lesion characteristics, imaging features, stent fracture, and end point observation indexes were analyzed by regression analysis.

Registry
clinicaltrials.gov
Start Date
September 30, 2021
End Date
December 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

12-month Primary Patency Rate

Time Frame: 12 months

systolic velocity ratio \>2.4 as measured by Duplex ultrasound.

Secondary Outcomes

  • 12-month Limb Salvage Rate(12 months)
  • Major Adverse Events at 12-month Post Procedure(12 months)
  • Technical success rate(1 day)
  • freedom from clinically-driven TLR rate(12 months)

Study Sites (1)

Loading locations...

Similar Trials